Last reviewed · How we verify

Ticagrelor Oral Tablet - Pre-Treatment

SFJ Pharmaceuticals, Inc. · Phase 2 active Small molecule

Ticagrelor Oral Tablet - Pre-Treatment is a Small molecule drug developed by SFJ Pharmaceuticals, Inc.. It is currently in Phase 2 development.

At a glance

Generic nameTicagrelor Oral Tablet - Pre-Treatment
SponsorSFJ Pharmaceuticals, Inc.
ModalitySmall molecule
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Ticagrelor Oral Tablet - Pre-Treatment

What is Ticagrelor Oral Tablet - Pre-Treatment?

Ticagrelor Oral Tablet - Pre-Treatment is a Small molecule drug developed by SFJ Pharmaceuticals, Inc..

Who makes Ticagrelor Oral Tablet - Pre-Treatment?

Ticagrelor Oral Tablet - Pre-Treatment is developed by SFJ Pharmaceuticals, Inc. (see full SFJ Pharmaceuticals, Inc. pipeline at /company/sfj-pharmaceuticals-inc).

What development phase is Ticagrelor Oral Tablet - Pre-Treatment in?

Ticagrelor Oral Tablet - Pre-Treatment is in Phase 2.

Related